Breast Cancer Subtypes Based on ER/PR and Her2 Expression: Comparison of Clinicopathologic Features and Survival

Onitilo, Adedayo A.; Engel, Jessica M.; Greenlee, Robert T.; Mukesh, Bickol N.

doi:10.3121/cmr.2009.825

Cited by 536 publications

(407 citation statements)

References 28 publications

(16 reference statements)

Supporting

Mentioning

366

Contrasting

Unclassified

Order By: Relevance

“…Breast cancer is not a single disease [38]: breast cancer prognosis varies with expression of key hormone receptors: estrogen receptor (ER), progesterone receptor (PR) and her2/neu/ ERbB2 (Her2) [56] histologic grade [57], and presence of metastasis. Recent evidence suggests that the microenvironment in these tumors is different [58,59].…”

Section: Breast Cancer Subtypesmentioning

confidence: 99%

The extracellular matrix in breast cancer predicts prognosis through composition, splicing, and crosslinking

Robertson

2016

Experimental Cell Research

View full text Add to dashboard Cite

The extracellular matrix in breast cancer predicts prognosis through composition, splicing, and crosslinking a b s t r a c tThe extracellular matrix in the healthy breast has an important tumor suppressive role, whereas the abnormal ECM in tumors can promote aggressiveness, and has been linked to breast cancer relapse, survival and resistance to chemotherapy. This review article gives an overview of the elements of the ECM which have been linked to prognosis of breast cancers, including changes in ECM protein composition, splicing, and microstructure. Published by Elsevier Inc.

show abstract

Section: Breast Cancer Subtypesmentioning

confidence: 99%

The extracellular matrix in breast cancer predicts prognosis through composition, splicing, and crosslinking

Robertson

2016

Experimental Cell Research

View full text Add to dashboard Cite

show abstract

“…The tumours were classified as ER/PR+,HER2+ (Luminal B); ER/PR+, HER2-(Luminal A); ER/PR-,HER2+; ER/PR-,HER2-(Triple negative) [17]. We found statistically significant correlation between IL 10 expression and ER/PR-, HER2+ subtype.…”

Section: Resultsmentioning

confidence: 77%

“…Triple negative tumours and ER-ve, PR-ve and HER2 + ve tumours are of worse prognosis among the different sub types [17,25,26]. A few studies even associated ER-ve, PR-ve and HER2 + ve sub types with worst prognosis among the different subtypes [27,28].…”

Section: Follow Upmentioning

confidence: 99%

Is Interleukin 10 (IL10) Expression in Breast Cancer a Marker of Poor Prognosis?

Bhattacharjee

Bansal

Nepal

et al. 2016

Indian J Surg Oncol

View full text Add to dashboard Cite

Interleukin 10 (IL10) is a poor prognostic marker in several cancers. Its role in breast cancer is not well elucidated. The present study is designed to see the expression of IL10 in breast cancer tissue and to evaluate its correlation with the established markers of prognosis. Sixty female patients who underwent surgery for breast cancer were enrolled for the study. Immediately after surgery, 2-5 g of tumour tissue and similar volume of peritumoural normal breast tissue were collected for IL10 assay. IL10 expression was assayed by immunohistochemistry. IL10 expressing tumours and IL10 non expressing tumours were compared. Chi square/Fisher exact test and student's t test were used to compare the data. p-valueless than 0.05 was considered as statistically significant. Thirty six patients (60 %) of carcinoma breast showed IL 10 expression in tumour tissue as compared to no IL 10 expression in any peritumouralnormal breast tissue (p < 0.01). IL10 expression had statistically significant correlation with locally advanced disease, tumour grade, HER2 + ve tumours and ER-ve, PR-ve, HER2 + ve breast cancer subtypes (p = 0.001, 0.001, 0.001 and 0.01 respectively). No correlation could be found with patient's age, tumour size, tumour histology and ER and PR status. Correlation of IL10 expressing tumours with several established poor prognostic markers of breast cancer may indicate the possible association of IL10 expression with poor prognosis. Large studies with long term follow up are needed to substantiate the association of IL10 with poor prognosis.

show abstract

“…It is the fifth leading cause of cancer related deaths in women worldwide. therapies have lead to steep falls in mortality rates [6].…”

Section: Introductionmentioning

confidence: 99%

Epitope presentation is an important determinant of the utility of antigens identified from protein arrays in the development of autoantibody diagnostic assays

Murphy

O’Connell

O’Kane

et al. 2012

Journal of Proteomics

View full text Add to dashboard Cite

* These authors contributed equally.Autoantibodies represent an attractive biomarker for diagnostic assays principally due to the stability of immunoglobulin in patient serum facilitating measurement with conventional assays. Immune responses to tumorigenesis may facilitate detection of ovarian cancer in the early stages of the disease with identification of a panel of tumour specific autoantibodies. Despite the reporting of many tumour associated autoantibodies using arrays of tumour antigens, this has not led to the advance in diagnostic capability as rapidly as was initially expected. Here we examine the potential diagnostic utility of candidate autoantibody biomarkers identified via screening of serum samples on a high content human protein array from a unique cohort of early stage and late stage ovarian cancer patients. We analyse the performance of autoantibodies to the tumour suppressor protein p53 and the novel autoantigens alpha adducin and endosulfine alpha identified in our array screen. Each antigen has different performance characteristics using conventional ELISA format and Western blot immunoassay. The high attrition rate of promising autoantigens identified by array screening can in part be explained by the presentation of the epitope of the antigen in the subsequent method of validation and this study provides directions on maximising the potential of candidate biomarkers. The most commonly used biomarker for ovarian cancer is Cancer Antigen 125 (CA125) or Mucin16 which is thought to provide a protective, lubricating barrier against particles and infectious agents at mucosal surfaces [9]. Elevated levels of this antigen are detected in over 90% of sera of disseminated ovarian cancer cases but only in 50% of patients in the early stages of the disease [10]. CA 125 screening is used with the addition of ultrasound screening. Although these combined approaches A C C E P T E D M A N U S C R I P T ACCEPTED MANUSCRIPT Materials and Methods Serum Sample DetailsSerum samples and clinical information was obtained with informed consent and study approval was obtained from St. James's Hospital and Adelaide and Meath incorporating the National Childerns Hospital research ethics committee.Pre-operative bloods were obtained from patients undergoing cytoreductive surgery for possible ovarian neoplasm. Blood was collected into a non-heparinised tube and allowed to clot, then centrifuged at 400 x g for 15 min. The serum supernatant was removed and dispensed into labelled cryovial tubes. Serum was stored at -80 o C until further use. hEx1 Serum Screening of Ovarian Cancer SamplesThe hEx1 array PVDF membranes (each hEx1 array is made up of 2 PVDF membranes, pt 8 and pt 9) were activated in ethanol for 1 min, rinsed in deionised water and washed in tris-buffered saline-T-T (500mM NaCl, 10mM Tris-HCl pH 7.5, 0.05% v/v Tween, 0.5% v/v Triton X ). Dessicated bacterial colonies were removed with tissue. The arrays washed in TBS-T-T for 10 min, TBS-T (500mM NaCl, 10mMTris-HCl pH 7.5, 0.05% v/v Tween) for 10 min and TB...

show abstract

Breast Cancer Subtypes Based on ER/PR and Her2 Expression: Comparison of Clinicopathologic Features and Survival

Cited by 536 publications

References 28 publications

The extracellular matrix in breast cancer predicts prognosis through composition, splicing, and crosslinking

The extracellular matrix in breast cancer predicts prognosis through composition, splicing, and crosslinking

Is Interleukin 10 (IL10) Expression in Breast Cancer a Marker of Poor Prognosis?

Epitope presentation is an important determinant of the utility of antigens identified from protein arrays in the development of autoantibody diagnostic assays

Contact Info

Product

Resources

About